Pharmaceuticals News and Research

RSS

House panel passes protection for drug makers

The House Energy and Commerce Committee passed an amendment to their broad health reform bill giving drug makers 12 years of exclusive rights to market new biologic drugs, "a setback" to the administration and consumer advocates who hoped to make generic drugs more widely available, the Wall Street Journal reports.

3 Aug 2009

House recesses, Democrats reflect on accomplishments and what's ahead

House Democrats celebrated late last week the passage of a health reform bill out of the House Energy and Commerce Committee, but they still face a lot of work when they return in September, Roll Call reports.

3 Aug 2009

AFP examines debate over H1N1 spending, resource allocation

There is concern that as developed countries store away antivirals, face masks and vaccines to protect against the H1N1 (swine) flu virus, poor countries are being left empty handed. "Some critics say the spending is so imbalanced that it amounts to health apartheid, protecting rich countries against H1N1 but leaving poor nations to fend for themselves," the news service writes, adding, "Others argue gargantuan sums are being spent on a disease that is no more lethal than seasonal flu, which is grotesquely disproportionate when thousands die each day of less media-friendly diseases."

3 Aug 2009

Health care industry increases lobbying spending

Drug companies "boosted their lobbying in Washington during the three months (that) ended June 30 amid a flurry of congressional action on health care," while overall, "Washington's lobbying business continued to slump as the economy pinched budgets at some big companies and trade associations," The Wall Street Journal reports.

3 Aug 2009

US FDA approves Lipsovir for cold sores

The US Food and Drug Administration (FDA) has now approved Lipsovir, i.e. granted Medivir's New Drug Application (NDA) for the use of acyclovir and hydrocortisone for early treatment of recurrent cold sores to decreases the risk of cold sores, and to shorten the healing time for those cold sores which are not prevented.

3 Aug 2009

FDA approves Invega Sustenna for schizophrenia

The U.S. Food and Drug Administration today approved Invega Sustenna (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults.

2 Aug 2009

FDA approves Onglyza (saxagliptin) for type 2 diabetes

The U.S. Food and Drug Administration has approved Onglyza (saxagliptin), a once-daily tablet to treat Type 2 diabetes in adults. The medication is intended to be used with diet and exercise to control high blood sugar levels.

2 Aug 2009

Tarceva shown to extend survival in advanced non-small cell lung cancer when used after initial chemo

OSI Pharmaceuticals, Inc. has announced further results from the Phase III SATURN study showing that Tarceva® (erlotinib) extended the survival of patients with advanced non-small cell lung cancer (NSCLC) when used as single agent, maintenance therapy in patients who did not progress following first-line treatment with platinum-based chemotherapy.

2 Aug 2009

Industry lobby wars heighten as reform efforts progress

"Healthcare companies are spending millions of dollars and marshaling armies of lobbyists to influence a landmark debate in the U.S. Congress that could dramatically change the way they do business," Reuters reports.

31 Jul 2009

Common food additive lecithin may help control blood lipids and reduce disease risk

Scientists at Washington University School of Medicine in St. Louis have identified a substance in the liver that helps process fat and glucose. That substance is a component of the common food additive lecithin, and researchers speculate it may one day be possible to use lecithin products to control blood lipids and reduce risk for diabetes, hypertension or cardiovascular disease using treatments delivered in food rather than medication.

31 Jul 2009

Lobbyists continue pressing their cases on health reform

Pharmaceutical companies, hospitals, advocacy groups and others with a stake in health reform continue to lobby in hopes of winning concessions in the overhaul, or at least surviving the changes unscathed.

30 Jul 2009

Colchicine approved for acute gout, Mediterranean fever

The U.S. Food and Drug Administration has approved Colcrys to treat acute flairs in patients with gout, a recurrent and painful form of arthritis, and patients with familial Mediterranean fever (FMF), an inherited inflammatory disorder. The medication's active ingredient is colchicine, a complex compound derived from the dried seeds of a plant known as the autumn crocus or meadow saffron (Colchicum autumnale).

30 Jul 2009

Massachusetts to restore immigrant health care, Colorado Medicaid list grows, Obama in North Carolina

Massachusetts lawmakers will vote today to provide $40 million to restore health care coverage for legal immigrants. In Colorado, a 14 percent spike in Medicaid capped a record year for enrollment.

30 Jul 2009

Swine Flu - getting drugs to the market more rapidly

The pharmaceutical industry has been up in arms this year. Giants such as Pfizer, GSK and AstraZeneca are looking for deals in the downturn whilst competing against increasing generic competition as some of the best selling medicines are coming off patent. In addition to the sectors ever-changing landscape companies are under tremendous pressure from governments to combat the Swine flu pandemic that has gripped the world.

29 Jul 2009

Majority of health care leaders support public health care option

By a wide margin, health care leaders believe that individuals should have a choice of public and private health plans, and strongly support other central components of health reform such as innovative provider payment reform and a national insurance health exchange with strong standard-setting authority.

28 Jul 2009

Adding a drug called neostigmine to epidural analgesia reduces dose needed during labor

Adding a drug called neostigmine to epidural analgesia during labor can reduce the amount of anesthetic drug required, while avoiding potential complications caused by morphine-like "opioid" drugs, according to a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

27 Jul 2009

New system may allow use of xenon to protect newborn brain

Breathing xenon gas can help protect the infant brain from damage caused by oxygen deprivation, but the xenon's high cost and scarcity has precluded its widespread use.

27 Jul 2009

Scientists make liquid protein

The first known example of a liquid protein has been made by chemists at the University of Bristol opening up the possibility of a number of medical and industrial applications including high-potency pharmaceuticals and protein-based coolants and lubricants.

23 Jul 2009

Costly biologics drugs prompt exclusivity debate

"A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?" The New York Times reports.

22 Jul 2009

Some health groups increase lobbying spending, but only a slight rise overall

"Drug makers, advocacy groups, biotechnology firms and insurance companies have ratcheted up efforts to offer their two cents - and in most cases much, much more - in influencing the health care legislation now working its way through Congress," The New York Times reports.

22 Jul 2009